drugset / Trial / NCT04030429
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
Phase 2
Terminated
40 enrolled
National Cheng-Kung University Hospital
Chi Mei Medical Hospital · collabKaohsiung Medical University · collabKaohsiung Veterans General Hospital. · collab
NaSingle-groupOpen-labelTreatment
Summary
The majority of endometrial cancer patients with disease spread beyond the uterus will progress within 1 year. Platinum-based chemotherapy was used as the first-line treatment in metastatic or advanced endometrial cancer. There is no standard protocol for the second-line option when tumors persist or recur. In vitro and in vivo studies showed Crizotinib, an approved drug for the treatment of ALK-positive non-small cell lung cancer, demonstrated activities in endometrial cancer with c-MET kinase and Sema domain mutations. As a consequence, a phase 2 clinical trial to investigate the efficacy of Crizotinib in endometrial cancer patients with MET mutation is initiated.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2025-06-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | 250 mg | Oral |